Will Sera Prognostics stock go up?

According to Danelfin AI, Sera Prognostics has today an AI Score of 6/10 (Hold rating), because its probability of beating the market in 3 months (54.45%) is +3.63% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Sera Prognostics stock?

The Sera Prognostics target price is $2.02 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Sera Prognostics stock right now?

Sera Prognostics has today a Hold rating (AI Score 6/10), according to Danelfin AI. Its probability of beating the market in 3 months (54.45%) is +3.63% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Sera Prognostics stock is a good buy .

Is Sera Prognostics undervalued right now?

Based on analysts, the average price target downside for Sera Prognostics is 0.00% (1Y). According to Danelfin AI, Sera Prognostics has today an AI Score of 6/10 (Hold Rating).

What was the price range of Sera Prognostics stock over the past 12 months?

The Sera Prognostics stock price range over the past 12 months has been $1.59 - $4.09.

What is going on with Sera Prognostics stock in the last 3 months?

The Sera Prognostics stock performance in the last quarter has been -2.41%.

Does Sera Prognostics offer dividend payments?

No, Sera Prognostics does not currently pay dividends.

What is the current market capitalization of Sera Prognostics?

Sera Prognostics's market cap is $78.32M, as of 2026-07-03 08:00.

Sera Prognostics Inc (SERA) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

SERA AI-Powered Stock Analysis

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Earnings Quality+3.01%
Stability and reliability of reported earnings
Momentum+1.83%
Direction and strength of recent price movements
Sentiment+0.66%
How analysts and the market view the stock
Valuation+0.65%
How the stock is priced relative to its fundamentals

Profitability-1.35%
Profitability and operating efficiency metrics
Size & Liquidity-1.06%
Company size and trading liquidity
Volatility-0.11%
How much the stock price tends to fluctuate

SERA probability advantage of beating the market (3M):

+3.63%

AI Score

Hold

Sera Prognostics (SERA) has an AI Score of 6/10 (Hold) because, according to an overall analysis, it has a probability advantage of +3.63% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of SERA (54.45%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
SERA probability advantage of beating the market (3M)+3.63%
SERA probability of beating the market (3M)54.45%

SERA probability advantage of beating the market (3M): +3.63%

The AI-powered overall analysis of Sera Prognostics (SERA) is based on the 28 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of SERA:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Operating Cash Flow (Qtr Discrete)	-8.77		+2.72%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-1.24%
Fundamental	Beginning Cash (Millions)	3.94		-1.06%
Fundamental	Gross Profit	-0.03	N/A	-0.93%
Technical	Distance from KAMA (20d)	0.06%		-0.90%
Technical	Technicals Impact (Long Tail)	-	N/A	+0.82%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+0.77%
Technical	Normalized Average True Range (50d)	9.61%		-0.77%
Technical	Alpha 6M	-0.39%		-0.71%
Sentiment	Industry (GICS)	Biotechnology	N/A	+0.69%
Technical	Upgrade to unlock			+0.65%
Technical	Upgrade to unlock			+0.65%
Fundamental	Upgrade to unlock			-0.64%
Sentiment	Upgrade to unlock			+0.64%
Technical	Upgrade to unlock			+0.58%

Rest of Alpha Signals: +2.35%

SERA probability advantage of beating the market (3M)Total:+3.63%
SERA AI Score

Significant changes Vs previous day

SERA Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$2.02
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

SERA Proven Hold Signal & Price Forecast

This is the price chart for SERA from January 2, 2026 until today. The chart indicates, in yellow, the 51 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

SERA Average Past Performance & Win Rate

Three months after its 533 Hold signals since July 2026, SERA had an average performance of xxxxxxx and a xxxxxx Win rate (positive performance).

533 Past SERA Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+40.32%
Average Alpha				+24.57%
Win Rate (% Positive Perf.)				35.71%
% Positive Alpha				33.44%

SERA Frequently Asked Questions

Will Sera Prognostics stock go up?
According to Danelfin AI, Sera Prognostics has today an AI Score of 6/10 (Hold rating), because its probability of beating the market in 3 months (54.45%) is +3.63% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Sera Prognostics stock?
Is it a good time to buy, sell, or hold Sera Prognostics stock right now?
Is Sera Prognostics undervalued right now?
What was the price range of Sera Prognostics stock over the past 12 months?
What is going on with Sera Prognostics stock in the last 3 months?
Does Sera Prognostics offer dividend payments?
What is the current market capitalization of Sera Prognostics?

Sera Prognostics Inc Company Profile

Sera Prognostics, Inc. is a diagnostic firm in the field of women's health that is actively involved in the identification, development and commercialization of biomarker tests aimed at enhancing pregnancy outcomes across the United States. Primary among its innovations is the PreTRM test, which is a blood-based biomarker test designed to assess the risk of spontaneous preterm birth in lone pregnancies.

Besides this flagship product, Sera Prognostics is also spearheading the creation of numerous other products, each tailored to address various pregnancy-related conditions. These conditions range from preterm birth and preeclampsia to molecular time-to-birth predictions. The company's portfolio further encompasses products supporting predictive analytics, geared towards gestational diabetes mellitus, fetal growth restriction as well as stillbirths.

In addition to these areas of focus, Sera Prognostics is charting new paths into postpartum depression prognosis and treatment possibilities. Since its inception in 2008, it has established its corporate headquarters in Salt Lake City, Utah where it continues to drive innovation in women's healthcare diagnostics through research and development efforts.

Sector:
Country:United States
Industry:
Address:2749 E. Parleys Way, Suite 200, Salt Lake City
Employees:72
Website:sera.com

Pros

Proprietary proteomic platform for maternal health

High switching costs for integrated diagnostic tests

Regulatory barriers to entry for novel diagnostics

Large unmet medical need in preterm birth prediction

Potential for improved patient outcomes reducing healthcare costs

Cons

Dependence on favorable reimbursement policy adoption

High capital expenditure for research and development

Slow clinical adoption cycles for new diagnostic tests

Intense competition from emerging diagnostic technologies

Concentration risk with large healthcare system customers

Company	AI Score	Compare
MCRBSeres Therapeutics Inc
NTRANatera Inc
PRLDPrelude Therapeutics Inc
PRQRProQR Therapeutics NV
SEERSeer Inc

Company	AI Score	Compare
MCRBSeres Therapeutics Inc
NTRANatera Inc
PRLDPrelude Therapeutics Inc
PRQRProQR Therapeutics NV
SEERSeer Inc

SERA Stock AI Analysis